HMGA2 and cancer: In particular, miR-34 controls BCL2, NOTCH, and the high mobility group AT-Hook 2 (HMGA2) in gastric cancer and MYC and MET in ovarian cancer [62,63], while miR-200 controls zinc finger E-box binding homeobox (ZEB)1, BM1, CNNB1, FN1, LEPR, and NTRK2, and inhibits cellular growth and metastasis in several cancers, including nasopharyngeal, pancreatic, and breast cancer [64,65].